Study of DTwP-HepB-Hib-IPV (SHAN6 ™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand

Conditions:   Pertussis Immunisation;   Diphtheria Immunisation;   Polio Immunisation;   Hepatitis B Immunisation;   Haemophilus Influenzae Type B Immunisation;   Tetanus Immunisation;   Rotavirus Immunisation;   Pneumococcal Immunisation Interventions:   Biological: DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus);   Biological: DTwP-HepB-Hib pentavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b);   Biological: Inactivated Poliomyelitis Vaccine;   Biological: Poliomyelitis Vaccine bivalent types 1 and 3;   Biological: Human Rotavirus, live attenuated;   Biological: Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) Sponsor:   Sanofi Pasteur, a Sanofi Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials